Oral Drug Filgotinib Approved for Axial Spondyloarthritis
Adults with active axial spondyloarthritis who have not responded to standard care now have an oral once-daily option in the EU.
Updated on Nov. 6, 2026 in Arthritis

The European Commission has approved expanded use of Jyseleca (filgotinib) for adults with active axial spondyloarthritis who have not responded adequately to conventional therapy, covering both radiographic and non-radiographic forms. Alfasigma has also submitted a marketing authorisation application to the UK MHRA, which is currently under review.
Why it matters
The approval adds an oral, once-daily option for people whose axial spondyloarthritis is not controlled by standard treatment, a population that has had fewer targeted choices. It extends filgotinib's authorised use beyond rheumatoid arthritis and ulcerative colitis, and the UK filing could bring the same option to British patients.
Two randomised, double-blind Phase III trials enrolled 258 patients with radiographic axial spondyloarthritis and 237 with non-radiographic disease, comparing once-daily oral filgotinib 200mg with placebo. Both met their primary endpoint at week 16, with ASAS40 response rates of 39.5% vs. 20.9% and 34.5% vs. 17.8% respectively.
The players
Alfasigma
An Italian pharmaceutical company focused on gastroenterology, rheumatology and related therapeutic areas, and the marketer of Jyseleca.
European Commission
The executive body of the European Union that grants marketing authorisations for medicines across member states.
Medicines and Healthcare products Regulatory Agency (MHRA)
The UK's national regulator responsible for approving medicines and medical devices for use in the United Kingdom.
The details
Filgotinib is an oral, once-daily tablet taken at 200mg in the trials, and the programme enrolled patients who had either not tolerated or not responded sufficiently to standard care. The ASAS40 measure used in the studies counts a response when a patient shows at least a 40% improvement on the Assessment of SpondyloArthritis international Society criteria. Jyseleca is already authorised in tablet strengths of 100mg and 200mg for other inflammatory conditions.
Timeline
Week 16: both Phase III trials reached their primary endpoint.
November 6, 2026: the European Commission's expanded approval for axial spondyloarthritis was announced.
August 2026: Alfasigma agreed to purchase Nordic Group, which is expanding into Canada.
Health Landscape
Axial spondyloarthritis has traditionally been managed with conventional therapies, with biologic options used for patients who do not respond. Adding an oral targeted option for both radiographic and non-radiographic disease widens the set of treatment choices available in this condition.
If you have been diagnosed with axial spondyloarthritis and standard treatment has not controlled your symptoms, this expanded indication is worth raising with your rheumatologist as a possible option. Because the trial data cover patients who had not responded adequately to conventional therapy, your physician is the right person to judge whether it fits your situation.
The takeaway
Filgotinib now has an approved oral option for adults with active axial spondyloarthritis who have not responded to conventional therapy, backed by two Phase III trials. If you live with this condition, ask your rheumatologist whether a targeted oral treatment could be appropriate for your disease pattern.
What happens next
The UK MHRA's decision on Alfasigma's marketing authorisation application for filgotinib is pending.
Further reading
For broader context on treatment options, explore our Arthritis coverage.
Source note: This article includes information reported by Pharmaceutical Technology.


